Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
記事の要約
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
信頼できる媒体の最新ニュースを短い要約で確認できます。詳細は元記事のリンクをご覧ください。